Literature DB >> 12624792

Role of protein kinase B in Alzheimer's neurofibrillary pathology.

Jin-Jing Pei1, Sabiha Khatoon, Wen-Lin An, Maria Nordlinder, Toshihisa Tanaka, Heiko Braak, Ichiro Tsujio, Masatoshi Takeda, Irina Alafuzoff, Bengt Winblad, Richard F Cowburn, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

Protein kinase B (PKB) is an important intermediate in the phosphatidylinositol-3 kinase signaling cascade that acts to phosphorylate glycogen synthase kinase-3 (GSK-3) at its serine 9 residue, thereby inactivating it. Activated GSK-3 has been previously shown to be preferentially associated with neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) brain. In the present study, we performed immunohistochemistry with an antibody to the active form of PKB in brains with different stages of neurofibrillary degeneration. We found that the amount of activated PKB (p-Thr308) increased in correlation to the progressive sequence of AT8 immunoreactivity and neurofibrillary changes assessed according to Braak's criteria. By confocal microscopy, activated PKB (p-Thr308) was found to appear in particular in neurons that are known to later develop NFTs in AD. Western blotting showed that activated PKB was increased by more than 50% in the 16,000- g supernatants of AD brains as compared with normal aged and Huntington's disease controls. This increase in PKB levels corresponded with a several-fold increase in the levels of total tau and abnormally hyperphosphorylated tau at the Tau-1 site. These studies suggest the involvement of PKB/GSK-3 signaling in Alzheimer neurofibrillary degeneration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12624792     DOI: 10.1007/s00401-002-0657-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  52 in total

1.  PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Authors:  Shira Knafo; Cristina Sánchez-Puelles; Ernest Palomer; Igotz Delgado; Jonathan E Draffin; Janire Mingo; Tina Wahle; Kanwardeep Kaleka; Liping Mou; Inmaculada Pereda-Perez; Edvin Klosi; Erik B Faber; Heidi M Chapman; Laura Lozano-Montes; Ana Ortega-Molina; Lara Ordóñez-Gutiérrez; Francisco Wandosell; Jose Viña; Carlos G Dotti; Randy A Hall; Rafael Pulido; Nashaat Z Gerges; Andrew M Chan; Mark R Spaller; Manuel Serrano; César Venero; José A Esteban
Journal:  Nat Neurosci       Date:  2016-01-18       Impact factor: 24.884

2.  The PTEN phosphatase is essential for long-term depression of hippocampal synapses.

Authors:  Yue Wang; Aiwu Cheng; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

3.  Presenilins regulate the cellular level of the tumor suppressor PTEN.

Authors:  Han Zhang; Runzhong Liu; Ruishan Wang; Shuigen Hong; Huaxi Xu; Yun-wu Zhang
Journal:  Neurobiol Aging       Date:  2007-01-12       Impact factor: 4.673

Review 4.  Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?

Authors:  Sónia C Correia; Renato X Santos; George Perry; Xiongwei Zhu; Paula I Moreira; Mark A Smith
Journal:  Ageing Res Rev       Date:  2011-01-22       Impact factor: 10.895

5.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

6.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

7.  The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid.

Authors:  Han-Kyu Lee; Pravir Kumar; Qinghao Fu; Kenneth M Rosen; Henry W Querfurth
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

8.  NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration.

Authors:  Young-Don Kwak; Tao Ma; Shiyong Diao; Xue Zhang; Yaomin Chen; Janet Hsu; Stuart A Lipton; Eliezer Masliah; Huaxi Xu; Francesca-Fang Liao
Journal:  Mol Neurodegener       Date:  2010-11-10       Impact factor: 14.195

Review 9.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.